Navigation Links
Potential new treatment may protect celiac patients from gluten-induced injury
Date:6/12/2014

Bethesda, MD (June 12, 2014) The gluten-specific enzyme ALV003 reduces a patient's exposure to gluten and its potential harm, according to a new phase 2 study appearing in Gastroenterology1, the official journal of the American Gastroenterological Association. This study is the first to find that a non-dietary intervention can potentially benefit celiac disease patients.

Study participants were put on an everyday gluten-free diet, challenged with up to 2 grams of gluten daily (equivalent to approximately one half of a standard slice of bread in the U.S.). Researchers found that daily oral administration of ALV003, at the time of gluten ingestion, decreased gluten-induced injury to the small intestine. The treatment appeared to be well tolerated. Gastrointestinal symptoms, such as nausea and abdominal pain, were greater in the placebo group compared with those receiving active treatment.

"Total avoidance of gluten is, at best, challenging," said lead study author, Marja-Leena Lahdeaho, University of Tampere, Tampere University Hospital, Finland. "The potential of ALV003 for celiac disease is significant given that ongoing exposure to low levels of gluten can cause patients to experience persistent symptoms and chronic intestinal inflammation, despite following a strict gluten-free diet."

Gluten is widely used in the food and other industries. Cross contamination during food processing is difficult to avoid and the labeling of food products can be inaccurate, misleading or incorrect. The gluten-free diet is socially troublesome, expensive and compliance is problematic. Additionally, traces of gluten can be found in common items such as envelope glue and makeup. These challenges lead to consumption of small amounts of gluten in even the most cautious patients. Thus, there is a need for the development of a pharmacologic therapy that will work with or replace a gluten-free diet.

As the first evidence of a therapeutic intervention for celiac disease meeting primary endpoints, this randomized, double-blind, placebo-controlled clinical trial is a welcomed addition to celiac research. Future studies are warranted before ALV003 can come to market; a 500-person multi-center trial is currently ongoing.


'/>"/>

Contact: Rachel Steigerwald
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related biology news :

1. Epigenetic signatures direct the repair potential of reprogrammed cells
2. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
3. Interventional radiology: Potential breakthrough to treat mens enlarged prostate
4. Researchers report potential for a moderate New England red tide in 2012
5. Gallbladder shown as potential stem cell source for regenerative liver and metabolic disease
6. Researchers find potential dark side to diets high in beta-carotene
7. Beehive extract shows potential as prostate cancer treatment
8. Gene therapy for hearing loss: Potential and limitations
9. Folic acid food enrichment potentially protective against childhood cancers
10. Nuisance seaweed found to produce compounds with biomedical potential
11. Potential new approach to regenerating skeletal muscle tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... 7, 2017 Report Highlights The ... from $8.3 billion in 2016 at a compound annual ... Report Includes - An overview of the global ... with data from 2015 and 2016, and projections of ... of the market on the basis of product type, ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/1/2017)... 2017 IDTechEx Research, a leading provider of ... the availability of a new report, Sensors for Robotics: Technologies, ... Reading ... ... Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... BEIJING, Feb. 23, 2017 China Biologic Products, Inc. ... integrated plasma-based biopharmaceutical company in China, today announced its financial ... Fourth Quarter 2016 Financial Highlights ... increased by 21.7% in RMB terms, or increased by 13.6% ... the same quarter of 2015. Gross profit ...
(Date:2/24/2017)... -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing ... Leader event to highlight new clinical data that will ... the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the Company,s ... in-person and via live webcast on Tuesday, February 28 ... the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... Calif., Feb. 23, 2017 ... dollars, except per share data, unaudited)Three Months Ended December ... BioMarin Revenue $     ... 22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... /PRNewswire/ - The Fight Against Cancer Innovation Trust (FACIT) ... pleased to report that Fusion Pharmaceuticals Inc. (Fusion) has ... Johnson Innovation – JJDC, Inc. (JJDC) as the lead ... Biotechnology Partners, and Genesys Capital, as well as founding ... ...
Breaking Biology Technology: